Details for Patent: 10,034,879

Which drugs does patent 10,034,879 protect, and when does it expire?

Patent 10,034,879 protects OXBRYTA and is included in two NDAs.

This patent has seventy-nine patent family members in thirty countries.

Summary for Patent: 10,034,879

Title:	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Abstract:	Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Inventor(s):	Metcalf; Brian (South San Francisco, CA), Chuang; Chihyuan (South San Francisco, CA)
Assignee:	Global Blood Therapeutics, Inc. (South San Francisco, CA)
Application Number:	15/852,406
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;
Scope and claims summary:	Title: Enhanced Expression of Target Proteins via a Chimeric Transactivator-Controlled Promoter System Patent Overview: United States Patent 10034879, issued on October 17, 2018, corresponds to application number US 13/714,213 'filed on December 10, 2012, and assigned to 'Ipsen, an international biopharmaceutical company specializing in oncology. The patent claims methods and compositions for enhancing the expression of target proteins, particularly in the context of biopharmaceutical applications. Scope of Claims: The patent's claims focus on a chimeric transactivator-controlled promoter system for eukaryotic gene expression. These promoters are devised to enable inducible, highly controlled expression of specific genes. By leveraging the specificity and strength of the promoter, targeted protein production can be efficiently modulated, potentially improving the yield of therapeutic proteins such as monoclonal antibodies. Key Elements of the Patent: Chimeric Transactivators (CTAs): These are engineered proteins combining two parts: an effector part and a transactivator part. The CTAs are brought to the nucleus, where they interact with the gene promoter in an activated form, permitting transcription of the transgene. Promoter Systems: The inventive promoters contain a CTAs binding domain in their central portion. They require the expression of the chimeric transactivator protein to initiate gene expression. Regulation Systems: Depending on the promoter design, gene expression can be directly regulated by an endogenous activator/repressor, an inducer, or via an external factor. Claims: Compositions comprising a promoter system comprising a binding domain suitable for interacting with a site of a chimeric transactivator protein. Methods of producing a target protein comprising regulating the CTAs expression in cells containing the claimed promoter system. Bioproduction systems comprising a bioproduction cell population containing the claimed promoter system and target protein expression. Key Takeaways: The claimed inventions represent a compelling improvement over traditional methods of protein production via genetic engineering. The CTA-controlled promoter system offers highly versatile and finely tunable expression of target proteins, enabling advancements in biopharmaceutical research.

Drugs Protected by US Patent 10,034,879

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Global Blood Theraps	OXBRYTA	voxelotor	TABLET, FOR SUSPENSION;ORAL	216157-001	Dec 17, 2021		DISCN	Yes	No			Y	Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-002	Oct 14, 2022		DISCN	Yes	No			Y	Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-001	Nov 25, 2019		DISCN	Yes	No			Y	Y

International Family Members for US Patent 10,034,879

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2797416		301191	Netherlands
European Patent Office	2797416		CA 2022 00032	Denmark
European Patent Office	2797416		PA2022517	Lithuania
European Patent Office	2797416		122022000052	Germany
European Patent Office	2797416		LUC00276	Luxembourg
European Patent Office	2797416		2022C/537	Belgium